Pfizer Acquires Prostate Drug Maker Medivation For $81.50, 21% Premium To Closing
August 22, 2016 at 13:25 PM EDT
Moments ago Pfizer, still stinging from its foiled mega-acquisition of Allergan earlier in the year, announced it would acquire prostate-cancer drug maker Medivation for $81.50, a 21% premium to the Friday closing price, in a $14 billion deal.
